Stewart TJ - Search Results

1

A role for CCL2 in both tumor progression and immunosurveillance.

Li M, Knight DA, A Snyder L, Smyth MJ, Stewart TJ. Li M, et al. Among authors: stewart tj. Oncoimmunology. 2013 Jul 1;2(7):e25474. doi: 10.4161/onci.25474. Oncoimmunology. 2013. PMID: 24073384 Free PMC article.

2

Chemokine-chemokine receptors in cancer immunotherapy.

Stewart TJ, Smyth MJ. Stewart TJ, et al. Immunotherapy. 2009 Jan;1(1):109-27. doi: 10.2217/1750743X.1.1.109. Immunotherapy. 2009. PMID: 20635978 Review.

3

Improving cancer immunotherapy by targeting tumor-induced immune suppression.

Stewart TJ, Smyth MJ. Stewart TJ, et al. Cancer Metastasis Rev. 2011 Mar;30(1):125-40. doi: 10.1007/s10555-011-9280-5. Cancer Metastasis Rev. 2011. PMID: 21249424 Review.

4

Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways.

Li M, Knight DA, Smyth MJ, Stewart TJ. Li M, et al. Among authors: stewart tj. Cancer Immunol Immunother. 2012 Aug;61(8):1255-68. doi: 10.1007/s00262-012-1200-1. Epub 2012 Jan 24. Cancer Immunol Immunother. 2012. PMID: 22270714 Free PMC article.

5

Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.

Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Stewart TJ, et al. Cancer Res. 2003 Jun 15;63(12):3058-60. Cancer Res. 2003. PMID: 12810627

6

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK. John LB, et al. Among authors: stewart tj. Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7. Cancer Res. 2012. PMID: 22315352

7

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH. Devaud C, et al. Among authors: stewart tj. Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19. Mol Ther. 2014. PMID: 24048441 Free PMC article.

8

Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms.

Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI. Greeneltch KM, et al. Among authors: stewart tj. Cancer Res. 2007 Nov 1;67(21):10406-16. doi: 10.1158/0008-5472.CAN-07-1228. Cancer Res. 2007. PMID: 17974984 Free article.

9

The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling.

Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, Borst J, Neefjes J. Verbrugge I, et al. Among authors: stewart tj. Radiat Res. 2014 Aug;182(2):219-29. doi: 10.1667/RR13511.1. Epub 2014 Jun 24. Radiat Res. 2014. PMID: 24960417

10

Immune consequences of protracted host-tumor interactions in a transgenic mouse model of mammary carcinoma.

Stewart TJ, Lutsiak ME, Abrams SI. Stewart TJ, et al. Cancer Invest. 2008 Apr-May;26(3):237-49. doi: 10.1080/07357900701708419. Cancer Invest. 2008. PMID: 18317964 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page